TIANXIN PHARMA(SH:603235)2023-10-30 16:00Financial Performance - The company's revenue for Q3 2023 was CNY 366,792,465.90, a decrease of 27.94% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2023 was CNY 82,946,828.20, down 44.68% year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 60,961,289.15, a decline of 56.65% compared to the previous year[8]. - The basic earnings per share for Q3 2023 was CNY 0.19, a decrease of 45.71% year-on-year[8]. - Total operating revenue for the first three quarters of 2023 was RMB 1,487,340,403.10, a decrease of 15.05% compared to RMB 1,750,311,425.71 in the same period of 2022[41]. - Net profit for the first three quarters of 2023 was RMB 412,902,988.52, a decline of 25.06% from RMB 551,180,610.84 in the same period of 2022[43]. - The company's total comprehensive income for the first three quarters of 2023 was impacted by a net loss from credit impairment of RMB 6,424,583.24, compared to RMB 2,674,032.35 in the previous year[43]. - The total comprehensive income attributable to the parent company was approximately CNY 412.90 million, a decrease from CNY 551.18 million in the previous year, representing a decline of about 25.1%[62]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,825,956,888.71, an increase of 3.12% from the end of the previous year[8]. - The total equity attributable to shareholders at the end of the reporting period was CNY 4,167,512,845.55, up 2.70% from the end of the previous year[8]. - The company's total liabilities and equity as of September 30, 2023, were RMB 4,825,956,888.71, compared to RMB 4,679,962,858.74 at the end of 2022[19]. - Total liabilities increased to CNY 640,955,018.02 from CNY 600,557,242.58 year-on-year[51]. - The company's total equity reached CNY 4,202,393,549.74, up from CNY 4,063,022,747.23 in the previous year[51]. Cash Flow - The company reported a cash flow from operating activities net amount of CNY 584,964,052.04, an increase of 19.43% year-to-date[8]. - Cash inflow from operating activities for the first three quarters of 2023 was CNY 1,406,321,475.27, a decrease of 17.0% compared to CNY 1,691,920,574.36 in the same period of 2022[46]. - Cash outflow from operating activities totaled CNY 987,055,521.20, down from CNY 1,299,253,547.49 in the previous year, resulting in a net cash flow from operating activities of CNY 584,964,052.04, an increase of 19.4% year-on-year[46]. - Cash inflow from investment activities was CNY 1,565,467,025.67, significantly higher than CNY 708,081,091.11 in the same period last year[47]. - The net cash flow from investment activities was negative at CNY -114,157,532.67, an improvement from CNY -917,529,639.73 in the previous year[47]. - The company's cash flow from financing activities was negative CNY 186.26 million, a significant decrease from positive CNY 1.29 billion in the previous year[75]. Expenses and Costs - Total operating costs for the first three quarters of 2023 were RMB 1,043,972,164.96, down 9.83% from RMB 1,157,637,647.72 in the previous year[41]. - Research and development expenses for the first three quarters of 2023 amounted to RMB 62,670,894.08, an increase from RMB 60,697,200.01 in the previous year[43]. - The company reported a decrease in sales expenses to RMB 22,737,280.40 from RMB 21,534,663.25 in the previous year[43]. - The company experienced a decrease in investment income to RMB 1,493,426.06 from RMB 2,789,856.46 in the previous year[43]. - Research and development expenses decreased to approximately CNY 29.15 million in 2023 from CNY 40.91 million in 2022, reflecting a reduction of 28.7%[53]. Market Conditions and Future Outlook - The decline in revenue and profit was attributed to weak downstream demand in the vitamin industry and a decrease in product prices compared to the previous year[11]. - The company experienced a significant reduction in foreign exchange gains compared to the same period last year, contributing to the profit decline[11]. - The company has not disclosed any new product developments or market expansion strategies in this report[10]. - The company plans to focus on market expansion and new product development in the upcoming quarters to drive future growth[54].